Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The results of two recent Phase III clinical trials indicate that docetaxel (Taxotere) extends life in advanced prostate cancer patients who are resistant to hormone therapy, supporting the Food and Drug Administration’s approval of docetaxel injection, in combination with prednisone, for the treatment of patients with advanced metastatic prostate cancer.

Docetaxel (Taxotere) extends life in advanced prostate cancer patients